Buy

FY25 OEM share of sales- M&M: 27%, Bajaj Auto: 14%, HMSI: 5%, MSIL:8% Q2FY26 Result: Lumax auto technologies posted robust Q2FY26 results. On the consolidated basis, total operating income came in at 1,156 crore (up 37% YoY). EBITDA in Q2FY26 came in at 155 crore with corresponding EBITDA margins at...

We maintain a BUY with a TP of Rs 610/share, reflecting 17% upside from the CMP.

Neogen Chemicals (Neogen) delivered a subdued financial performance in the quarter. Profitability was impacted on account of higher employee costs, rise in insurance premiums, increase in finance costs owing to rebuilding of the Dahej MPP (post the fire incident) and lower utilization and startup costs at Neogen Ionics. The demand for Electrolytes and Salts has been delayed by 6 to 12 months owing to the delays in EV ramp up. However we continue to remain positive on the battery chemicals theme as growth from EVs and Battery Energy Storage Systems (BESS) will necessitate the creation of a domestic supply...

We maintain our BUY rating on the stock.

Q2FY26 performance: Wabag reported steady operational performance in Q2FY26 with revenues growing 20% YoY to 834 crore. Material costs (limited by forex gain) impacted EBITDA margins, which fell 30 bps YoY to 14.4%, EBITDA up 17% YoY to 120.5 crore. PAT margins decline to 21 bps YoY at 9.7%. Consequently, PAT came in at 95 crore up 20% YoY. On a segmental basis, India (48% of revenue mix and international business (52%) grew 8% and 25% YoY. EBIT margins for India and International business at 17% and 26%, +280 bps and -1020 bps YoY. Wabag's unexecuted order book stood at ~16020crore with 3477 crore order inflow (80%...

We maintain our BUY recommendation on the stock.

We maintain our BUY recommendation on the stock.

Valuations at 9.1x EV/EBITDA & $70 EV/ton on FY27E, looks attractive, looking at company's strategic plan of achieving 30 mtpa by FY30E with favourable market mix. We maintain BUY on JKLC with TP of 1050 (based...

We maintain our BUY rating on the stock

With 9.7m cement tpa now, Star Cement is targeting 18m-20m tpa by FY30. Greater operational efficiency with the stabilised clinker unit, incentives from capacity commissioning and the rising share of green energy (aimed at 55-60%) would aid the operating performance.

With healthy volume growth and healthy improvement in EBITDA/ton over FY25-28E, we expect revenue to grow ~15% CAGR over FY25-28E while EBITDA & PAT are expected to grow at ~30% & ~50% CAGR respectively. We recommend BUY on Star Cement with a revised target price of Rs 300...

Quarterly Update Q2FY26

Gulf Oil (GOLI) delivered 10.6%/3.2% YoY growth in EBITDA/PAT to INR 1.19bn/INR 0.87bn (I-Sec: EBITDA/PAT INR 1.29bn/INR 0.99bn).

Q1FY26 business performance: CSB Bank reported healthy growth in Q1FY26, with gross advances up 31% YoY (3.3% QoQ) to 32,552 crore, led by gold loans (36% YoY), corporate (32%), SME (31%) and retail ex-gold (19%), while deposits rose 20.1% YoY (-2.5% QoQ) to 35,935 crore, supported by 22.3% YoY growth in term deposits. However, margin pressure persisted, with NIM contracting 21 bps QoQ to 3.54% due to excess liquidity and higher funding costs. Other income rose 42% YoY, with fee-based income up 22% YoY. Asset quality optically weakened, with GNPA rising 27 bps QoQ to 1.84%, though one large account has been...

We maintain our BUY rating on the stock.

We expect moderate multiple expansion as the bank sustains mid-teen RoE, stable margins, and continued balance sheet strengthening.

Well prepated for a long term sustainable growth developer and manufacturer of APIs (~93% of FY25 revenues) with major focus in chronic therapeutic areas such as cardiovascular disease, central nervous system disease, pain management and diabetes. GLS caters to over 700 customers in more...

About the stock: Allied Blenders & Distillers (ABDL), incorporated in 1988, is third largest IMFL company in terms of sales volumes between FY14-22. It has 18 IMFL brands in the portfolio; 4 out of it are Millionaire brands. Premiumisation is core of the long-term growth strategy. Prestige & Above (P&A) brands contribution increased to 40.4% in FY25 vs. 25% in FY18. Q2FY26 performance: ABDL's Consolidated net revenues 14.1% YoY growth to Rs.990.1cr driven by strong 28% volume growth in P&A segment (contributes 47% to overall volumes). Gross margins reported 158bps YoY improvement to 44.4% due...

Zydus Wellness (Zydus)’s Q2FY26 was a strategically important yet transitional quarter – strategic in direction but impacted by muted organic momentum amid GST-led disruption and seasonal weakness.

In Q2FY26, Blackbuck’s core revenues grew ~37% YoY led by 55% QoQ growth in fuel sensors. New businesses grew >2x YoY and 19% QoQ led by Superloads and vehicle financing.